Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions

Peter Valent*, Cem Akin, Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, Boguslaw Nedoszytko, Joseph H. Butterfield, Ivan Alvarez-Twose, Karl Sotlar, Juliana Schwaab, Mohamad Jawhar, Andreas Reiter, Mariana Castells, Wolfgang R. Sperr, Hanneke C. Kluin-Nelemans, Olivier Hermine, Jason Gotlib, Roberta Zanotti, Sigurd Broesby-Olsen, Hans Peter HornyMassimo Triggiani, Frank Siebenhaar, Alberto Orfao, Dean D. Metcalfe, Michel Arock, Karin Hartmann


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

146 Downloads (Pure)


The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19–induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation–related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti–mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.

TidsskriftJournal of Allergy and Clinical Immunology
Udgave nummer2
Sider (fra-til)300-306
StatusUdgivet - aug. 2020


Dyk ned i forskningsemnerne om 'Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions'. Sammen danner de et unikt fingeraftryk.